You’ve just had orthopedic surgery and have developed a post-operative infection. As part of your recovery regimen, your doctor suggests intravenous antibiotic therapy. Would you prefer to extend your stay in the hospital during your treatment or be discharged and receive this therapy in the comfort of your own home?
Historically, this type of care had been provided only in an in-patient, hospital setting and at an enormous expense to the health care system. However, the use of more cost-effective, alternate sites for infusion care delivery, including ambulatory (outpatient) settings and at a patient’s home, are rapidly growing in step with rising rates of conditions requiring intravenous therapies.
Through Coram, a service of CVS Health, we provide important infusion care in our many infusion suites throughout the country or in a patient’s home. Each month, we support tens of thousands of Americans who are managing a range of acute and chronic conditions requiring intravenous therapy, which can range from therapies for cystic fibrosis, rheumatoid arthritis and cancer to intravenous antibiotic treatment following orthopedic surgery, post-operative transplant support and enteral nutrition (tube feeding). Care is delivered by experienced infusion nurses and pharmacists, and 24/7 clinical and disease management support is also available.
Receiving infusion care at home is a convenient, safe and medically effective option for many patients who have chronic illness, are recovering from surgery or are being treated for an infection. It can also be a cost-effective alternative to placement in a nursing home or extending a hospital stay.
In fact, research from the CVS Health Research Institute shows that home infusion care is far more cost-effective than receiving this care in a medical facility. Researchers conducted a systematic review of existing literature evaluating infusion care and compared measures of quality, safety, clinical outcomes and costs. They found that patients receiving intravenous therapy at home had as good or better clinical outcomes as those patients who received the same therapy in a traditional health setting. Further, the payer costs associated with home infusion care were significantly lower, with savings ranging between $2,000 and $3,000 per treatment regimen. Patients also overwhelmingly preferred receiving intravenous therapy at home reporting fewer disruptions and better overall quality of care.
We are focused on improving patient outcomes and lowering costs and offering more effective sites of care. According to our Chief Medical Officer and study author, Troyen A. Brennan, MD, “our research shows that home infusion care is a promising model that is both cost and clinically effective and is overwhelmingly preferred by patients when intravenous therapy is required."